

Caring for your eyes while taking BLENREP



This guide will help you understand the eye problems that may occur during treatment.

Approved Use

BLENREP is a prescription medicine used in combination with the medicines bortezomib and dexamethasone to treat adults with multiple myeloma who:

- have received at least 2 prior treatments, including a proteasome inhibitor and an immunomodulatory agent, and
- their cancer has come back or did not respond to prior treatment

It is not known if BLENREP is safe and effective in children.

Important Safety Information

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:

- | | | | |
|--------------------|------------------------|--|------------------|
| - decreased vision | - dry eyes | - feeling like something is in your eyes | - eye irritation |
| - blurred vision | - sensitivity to light | | - eye pain |

Please see additional Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.



BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

About BLENREP

BLENREP is a targeted treatment that works in multiple ways




How BLENREP works

BLENREP binds to a protein found on the surface of myeloma cells called BCMA

BLENREP KILLS MYELOMA CELLS

by delivering the anti-cancer medicine into the cell



BLENREP TRIGGERS THE IMMUNE SYSTEM

as another way to kill multiple myeloma cells

BCMA is found at higher levels on myeloma cells. BLENREP can affect normal cells.

BLENREP is the first treatment of its kind and is given in combination with bortezomib and dexamethasone.

BLENREP has been associated with vision and eye changes. Because of this, you will be closely monitored for these types of changes during therapy.

Important Safety Information for BLENREP (cont'd)

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

How BLENREP may affect the surface of your eyes

Eye problems from BLENREP can happen from damage to the surface cells of the eye, specifically in the cornea. BLENREP is designed to attack cancer cells, but it can also have an effect on normal cells, causing changes to the surface layer of the eye.

Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam.

It's important to see an eye doctor (an ophthalmologist or optometrist) before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems.




Important Safety Information for BLENREP (cont'd)

Your healthcare provider will refer you to an eye care specialist (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

 **BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

What to expect when you start BLENREP




~30-minute infusion

BLENREP will be given to you through an intravenous (IV) infusion at a Risk Evaluation and Mitigation Strategy (REMS)-certified outpatient site, such as your doctor's office or an outpatient clinic. Timing will vary by patient, but can be as short as 30 minutes. **No hospitalization is needed to start treatment** with BLENREP.



Dosing schedule and blood monitoring

BLENREP is usually given **every 3 weeks**, in combination with bortezomib and dexamethasone for the first 8 cycles, then treatment continues with BLENREP alone. Your healthcare provider will decide how many treatments you will need, and will check your blood cell counts before you start treatment with BLENREP, and during treatment as needed.



Eye exams required before each dose

Eye exams are required before starting BLENREP, then repeated before each dose. Additional eye exams will also be needed for new or worsening symptoms or as your doctor recommends.

If you have side effects, your oncologist may adjust your dose.

- Adjustments may include an increase in time between doses or a decrease in dose
- If you experience serious side effects, your oncologist may temporarily or completely stop treatment with BLENREP
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment

Talk to your doctor for medical advice about side effects.

Important Safety Information for BLENREP (cont'd)

- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment. See **“What are the possible side effects of BLENREP?”** for more information about side effects.

What are the possible side effects of BLENREP?


BLENREP can cause serious side effects, including:

- See **“Eye Problems”** in **“What is the most important information I should know about BLENREP?”**

Important Safety Information for BLENREP (cont'd)

- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

Please see additional Important Safety Information throughout. Click to see the full Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.

 **BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

Side effects of BLENREP



The most important information you should know about BLENREP

BLENREP can cause serious side effects, including:

- **Eye problems**, which are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

Your healthcare provider will refer you to an eye doctor (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye doctor
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment.

Additional serious side effects can include:

- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

In addition to eye problems, the most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.


Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.

Please see Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

 **BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

Eye problems

Eye problems such as changes in vision are common with BLENREP

Changes in vision with BLENREP were measured by the eye chart exam known as the Best-Corrected Visual Acuity (BCVA) test.

In DREAMM-7, nearly all of the people (89%) who were treated with the BLENREP combination had a reduction in BCVA in at least 1 eye. This means their vision was less sharp even with corrective lenses.

For people who experienced a reduction in BCVA in at least 1 eye



Images are for illustrative purposes only. Vision will differ for each individual. Images created with an Eye Care Professional.

Talk to your doctor to learn more about changes in vision while taking BLENREP




Eye exams

Before each dose of BLENREP, your eye doctor will perform 2 common exams:



Best-Corrected Visual Acuity (BCVA) test

It measures how sharp your eyesight is, usually by reading an eye chart from a distance.



Slit lamp test

An eye doctor takes a closer look at the front and inside of your eye.

Important Safety Information for BLENREP (cont'd)

The most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- See "Eye problems" in "What is the most important information I should know about BLENREP?"
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

Please see additional Important Safety Information throughout. Click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

BLENREP
belantamab
mafodotin-blmf
for injection 70 mg

Important Safety Information for BLENREP

What is the most important information I should know about BLENREP?

BLENREP can cause serious side effects, including:

- **Eye problems.** Eye problems are common with BLENREP and can also be severe. BLENREP can cause changes to the surface of your eye, which can lead to symptoms of eye problems, including:
 - decreased vision
 - blurred vision
 - dry eyes
 - sensitivity to light
 - feeling like something is in your eyes
 - eye irritation
 - eye pain

Ulcers on the surface of the eye (corneal ulcers), including with infection, may also happen during treatment with BLENREP.

Tell your healthcare provider right away if you notice any new or worsening eye symptoms or vision changes during treatment with BLENREP.

Your healthcare provider will refer you to an eye care specialist (such as an ophthalmologist or optometrist) to check your eyes before you start treatment, before you receive each dose of BLENREP, and as needed for any new or worsening eye problems. **It is important that you:**

- Keep all of your eye care appointments because some changes can happen without symptoms and may only be seen on an eye exam
- Use preservative-free artificial tears at least 4 times per day starting with your first infusion and continuing until the end of treatment with BLENREP
- Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye care specialist
- Use caution when driving or operating machinery because BLENREP may cause changes to your vision

Because of the risk of eye problems, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider will give you the BLENREP REMS Patient Guide, which describes the risk of eye problems, and will explain the REMS program to you. To receive BLENREP, you must enroll in the REMS program and receive eye exams during treatment. See **“What are the possible side effects of BLENREP?”** for more information about side effects.

What are the possible side effects of BLENREP?

BLENREP can cause serious side effects, including:

- See **“Eye Problems”** in **“What is the most important information I should know about BLENREP?”**
- **Decrease in platelets (thrombocytopenia)** is common with BLENREP and can also be severe. Platelets are a type of blood cell that help your blood to clot. Your healthcare provider will check your blood cell counts before you start treatment with BLENREP and during treatment as needed. Tell your healthcare provider if you get any bleeding or bruising during treatment with BLENREP

The most common side effects of BLENREP when given with bortezomib and dexamethasone include:

- See **“Eye problems”** in **“What is the most important information I should know about BLENREP?”**
- upper respiratory tract infection
- liver problems
- diarrhea
- tiredness
- pneumonia
- cataract
- COVID-19

The most common severe abnormal blood test results during treatment with BLENREP include decreases in platelets, white blood cells, and hemoglobin, and increases in certain liver enzymes.

Tell your healthcare provider right away if you get new or worsening unexplained signs or symptoms of lung problems, including shortness of breath, chest pain, or cough.

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BLENREP if you get serious side effects.

BLENREP may affect fertility in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of BLENREP.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please click to see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#) for BLENREP.

 **BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

Important Safety Information for BLENREP (cont'd)

Before receiving BLENREP, tell your healthcare provider about all of your medical conditions, including if you:

- have or had vision or eye problems
- have or had bleeding problems
- are pregnant or plan to become pregnant. BLENREP can harm your unborn baby

Females who are able to become pregnant:

- Your healthcare provider will do a pregnancy test before you start treatment with BLENREP
- Use effective birth control during treatment with BLENREP and for 4 months after the last dose. Talk to your healthcare provider about birth control methods you can use during this time
- Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with BLENREP


Males with female partners who are able to become pregnant:

- Use effective birth control during treatment with BLENREP and for 6 months after the last dose
- are breastfeeding or plan to breastfeed. It is not known if BLENREP passes into your breast milk. Do not breastfeed during treatment with BLENREP and for 3 months after the last dose

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.

Please click to see the full [Prescribing Information, including Boxed Warning and Medication Guide for BLENREP.](#)

**BLENREP**
belantamab
mafodotin-blmf
for injection 70 mg

**If you haven't enrolled in
Together with BLENREP,
sign up today!**



Click the link below to enroll and access additional resources, Nurse Navigators,* and much more.



We are here to help!

You can reach your Nurse Navigator at
1-844-4GSK-ONC (1-844-447-5662)

Monday–Friday 8:00 AM–8:00 PM ET
Or visit togetherwithBLENREP.com

*The Nurse Navigator does not provide medical advice and is not a part of your doctor's care team. Please ask your doctor any questions that you might have about your disease and treatment with BLENREP.

**Please see Important Safety Information throughout.
Click to see the full Prescribing Information, including
Boxed Warning and Medication Guide for BLENREP.**

Trademarks are owned by or licensed to the GSK group of companies.



©2025 GSK or licensor.
PMUS-BLMLBND250039 December 2025
Produced in USA.

File Name: Caring for your Eyes



BLENREP
belantamab
mafodotin-blmf
for injection 70 mg